Lexicon Pharmaceuticals Announces Positive Topline Clinical Data for LX9211
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: GlobeNewswire
THE WOODLANDS, Texas, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline results from its Phase 1a study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1, or AAK1, in development for the treatment of neuropathic pain. "We are pleased that the initial clinical data for LX9211 confirms the drug candidate’s preclinical profile," said Praveen Tyle, Ph.D., executive vice president of Research and Development at Lexicon. "LX9211 was well tolerated with predictable pharmacokinetics. At doses tested, drug levels of LX9211 were at biologically relevant concentrations and support the therapeutic potential of this highly selective inhibitor of AAK1. We look forward to initiating a multiple ascending dose study for LX9211 in the first quarter of 2019.” The Phase 1a study met its primary objectives, demonstrating a favorable safety and tolerability profile in healthy human subjects and identifying the
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Lexicon Pharmaceuticals to Host 2024 Investor Day [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals to Host 2024 Investor DayGlobeNewswire
- All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
LXRX
Earnings
- 3/11/24 - Beat
LXRX
Sec Filings
- 3/26/24 - Form ARS
- 3/26/24 - Form DEFA14A
- 3/26/24 - Form DEF
- LXRX's page on the SEC website